PP
DOVA

Paloma Partners’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Paloma Partners’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-15,200
Closed -$214K – 2441
2019
Q2 		$214K Buy
+15,200
New +$145K ﹤0.01% 1509

Other funds holding DOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's DOVA Position: Q3 2019 in Review

Paloma Partners sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q3 2019, closing a stake of 15,200 shares — an estimated $214K sold.

Paloma Partners first reported a position in DOVA in Q2 2019 and held it in 1 quarter. The position peaked at $214K in Q2 2019. 72 funds tracked by Wall St. Rank hold DOVA as of Q3 2019.

  • Paloma Partners reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Paloma Partners sold 15,200 Dova Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $214K.
  • Paloma Partners first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Paloma Partners's Dova Pharmaceuticals, Inc. Common Stock position peaked at $214K in Q2 2019.
  • 72 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.